Acerca de

Axil Capital focuses on creating value in the life sciences venture ecosystem by actively supporting its portfolio companies in building commercially viable enterprises.

About

Axil Capital was spun out of Mizuho Securities in 2017, with early investors that include Mizuho, the Japanese government, a global pharmaceutical company, and a small group of corporate visionaries from inside and outside of Japan. Our goal is to create synergies between the biotech ecosystem in Japan and the rest of the world, to build companies with long term value and generate sustainable returns for our investors.

 

We specialize in identifying, evaluating, executing and nurturing our investments that span the full spectrum of the life science industry. We diversify our portfolio by investing in early-stage venture capital as well as late-stage crossover round deals. We focus on transformational technologies and services that can have a long-term impact on the medical community and society at large while generating tangible returns to our investors.

Our Strategies

Axil invests across the full spectrum of the global biotech and healthcare space, ranging from seed to crossover stage venture capital opportunities. We diversify our investments across a wide range of technologies in the life science field, including biopharmaceuticals, platform technologies, medical devices, digital health and healthcare services.

Our Business

Venture capital investments in the biomedical and healthcare technology fields.

Business Entities

Axil Capital Partners LLP

・Management and operation of venture capital funds. 

 

Axil Capital Advisors K.K.

・Research and analysis of investment opportunities. 

Axil Capital-07.png

Axil Capital Advisors K.K.

Nittochi Nishi-shinbashi Bldg. 7F

1-11-4 Nishi-shinbashi

Minato-ku, Tokyo 105-0003, JAPAN

© Axil Capital All Rights Reserved